Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer

被引：0

作者：

Davies, Rhian Sian ^{[1
]}

Smith, Christian ^{[1
]}

Lester, Jason Francis ^{[1
]}

机构：

[1] Velindre Canc Ctr, Cardiff, S Glam, Wales

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 04期

关键词：

Metastatic; castrate-resistant; prostate cancer; enzalutamide; third line; drug sequencing; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; PREDNISONE; MITOXANTRONE; MEN;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: There are no published randomised trials on the efficacy of enzalutamide against metastatic castrate-resistant prostate cancer (mCRPC) after docetaxel and abiraterone. We evaluated the activity of third-line enzalutamide in men with mCRPC after docetaxel and abiraterone. Patients and Methods: Progression-free (PFS) and overall (OS) survival from the start of enzalutamide were compared according to response to abiraterone in men with mCRPC treated at a single cancer centre. Results: Median PFS and OS for the whole 34-patient cohort from starting enzalutamide were 2.7 months (95% confidence interval=1.4-4.0 months) and 10.4 months (95% confidence interval=9.0-11.7 months). There was no significant difference in PFS and OS in patients according to prostate-specific antigen response to abiraterone (>= 50% vs. <50%, <= or >6 months). Conclusion: In mCRPC, enzalutamide has modest activity after docetaxel and abiraterone. Response to previous abiraterone is not predictive of subsequent enzalutamide response.

引用

页码：1799 / 1803

页数：5

共 13 条

[1] Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone [J].

Bianchini, D. ;

Lorente, D. ;

Rodriguez-Vida, A. ;

Omlin, A. ;

Pezaro, C. ;

Ferraldeschi, R. ;

Zivi, A. ;

Attard, G. ;

Chowdhury, S. ;

de Bono, J. S. .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) :78-84

[2] Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis [J].

Brasso, Klaus ;

Thomsen, Frederik B. ;

Schrader, Andres J. ;

Schmid, Sebastian C. ;

Lorente, David ;

Retz, Margitta ;

Merseburger, Axel S. ;

von Klot, Christoph A. ;

Boegemann, Martin ;

de Bono, Johann .

EUROPEAN UROLOGY, 2015, 68 (02) :317-324

[3] Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study [J].

Caffo, Orazio ;

De Giorgi, Ugo ;

Fratino, Lucia ;

Alesini, Daniele ;

Zagonel, Vittorina ;

Facchini, Gaetano ;

Gasparro, Donatello ;

Ortega, Cinzia ;

Tucci, Marcello ;

Verderame, Francesco ;

Campadelli, Enrico ;

Lo Re, Giovanni ;

Procopio, Giuseppe ;

Sabbatini, Roberto ;

Donini, Maddalena ;

Morelli, Franco ;

Sartori, Donata ;

Zucali, Paolo ;

Carrozza, Francesco ;

D'Angelo, Alessandro ;

Vicario, Giovanni ;

Massari, Francesco ;

Santini, Daniele ;

Sava, Teodoro ;

Messina, Caterina ;

Fornarini, Giuseppe ;

La Torre, Leonardo ;

Ricotta, Riccardo ;

Aieta, Michele ;

Mucciarini, Claudia ;

Zustovich, Fable ;

Macrini, Sveva ;

Burgio, Salvatore Luca ;

Santarossa, Sandra ;

D'Aniello, Carmine ;

Basso, Umberto ;

Tarasconi, Sara ;

Cortesi, Enrico ;

Buttigliero, Consuelo ;

Ruatta, Fiorella ;

Veccia, Antonello ;

Conteduca, Vincenza ;

Maines, Francesca ;

Galligioni, Enzo .

EUROPEAN UROLOGY, 2015, 68 (01) :147-153

[4] Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel [J].

Cheng, H. H. ;

Gulati, R. ;

Azad, A. ;

Nadal, R. ;

Twardowski, P. ;

Vaishampayan, U. N. ;

Agarwal, N. ;

Heath, E. I. ;

Pal, S. K. ;

Rehman, H-t ;

Leiter, A. ;

Batten, J. A. ;

Montgomery, R. B. ;

Galsky, M. D. ;

Antonarakis, E. S. ;

Chi, K. N. ;

Yu, E. Y. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (02) :122-127

[5]

Davies RS, 2015, ANTICANCER RES, V35, P5615

[6] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[7] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[8] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[9] Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer [J].

Parker, C. ;

Nilsson, S. ;

Heinrich, D. ;

Helle, S. I. ;

O'Sullivan, J. M. ;

Fossa, S. D. ;

Chodacki, A. ;

Wiechno, P. ;

Logue, J. ;

Seke, M. ;

Widmark, A. ;

Johannessen, D. C. ;

Hoskin, P. ;

Bottomley, D. ;

James, N. D. ;

Solberg, A. ;

Syndikus, I. ;

Kliment, J. ;

Wedel, S. ;

Boehmer, S. ;

Dall'Oglio, M. ;

Franzen, L. ;

Coleman, R. ;

Vogelzang, N. J. ;

O'Bryan-Tear, C. G. ;

Staudacher, K. ;

Garcia-Vargas, J. ;

Shan, M. ;

Bruland, O. S. ;

Sartor, O. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (03) :213-223

[10] Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy [J].

Scher, Howard I. ;

Fizazi, Karim ;

Saad, Fred ;

Taplin, Mary-Ellen ;

Sternberg, Cora N. ;

Miller, Kurt ;

de Wit, Ronald ;

Mulders, Peter ;

Chi, Kim N. ;

Shore, Neal D. ;

Armstrong, Andrew J. ;

Flaig, Thomas W. ;

Flechon, Aude ;

Mainwaring, Paul ;

Fleming, Mark ;

Hainsworth, John D. ;

Hirmand, Mohammad ;

Selby, Bryan ;

Seely, Lynn ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (13) :1187-1197

← 1 2 →